HN2012001413A - Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos - Google Patents

Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos

Info

Publication number
HN2012001413A
HN2012001413A HN2012001413A HN2012001413A HN2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A
Authority
HN
Honduras
Prior art keywords
treatment
neurological disorders
pirazine
derivatives
pirazine derivatives
Prior art date
Application number
HN2012001413A
Other languages
English (en)
Inventor
Marina Tintelnot-Blomley
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2012001413(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HN2012001413A publication Critical patent/HN2012001413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA INVENCION SE REFIERE A NOVEDOSOS COMPUESTOS HETEROCÍCLICOS DE LA FÓRMULA (I) EN DONDE TODAS LAS VARIABLES SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA, EN FORMA LIBRE ON EN FORMA DE SAL, A SU PREPARACIÓN A SU USO MÉDICO, Y A MEDICAMENTOS QUE LOS COMPRENDEN.
HN2012001413A 2009-12-31 2012-06-28 Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos HN2012001413A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31

Publications (1)

Publication Number Publication Date
HN2012001413A true HN2012001413A (es) 2015-03-23

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012001413A HN2012001413A (es) 2009-12-31 2012-06-28 Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos

Country Status (27)

Country Link
US (2) US20120277244A1 (es)
EP (1) EP2519515B1 (es)
JP (1) JP5600754B2 (es)
KR (1) KR101419157B1 (es)
CN (1) CN102712621B (es)
AU (1) AU2010338365B2 (es)
BR (1) BR112012015916A2 (es)
CA (1) CA2785341A1 (es)
CL (1) CL2012001762A1 (es)
CR (1) CR20120332A (es)
CU (1) CU20120099A7 (es)
EA (1) EA201200952A1 (es)
EC (1) ECSP12012065A (es)
ES (1) ES2445536T3 (es)
GT (1) GT201200219A (es)
HK (1) HK1172023A1 (es)
HN (1) HN2012001413A (es)
IL (1) IL220268A0 (es)
MX (1) MX2012007754A (es)
NZ (1) NZ600136A (es)
PE (1) PE20121640A1 (es)
PL (1) PL2519515T3 (es)
PT (1) PT2519515E (es)
SG (1) SG181431A1 (es)
TN (1) TN2012000249A1 (es)
WO (1) WO2011080176A1 (es)
ZA (1) ZA201203614B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0811034A2 (pt) 2007-04-24 2014-12-09 Shionogi & Co Derivados de aminodi-hidrotiazina substituídos com um grupo cíclico e seus usos e composições farmacêuticas
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
SG185652A1 (en) * 2010-06-09 2012-12-28 Janssen Pharmaceutica Nv 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
US20130109683A1 (en) 2010-06-09 2013-05-02 Janssen Pharmaceutica Nv 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
CA2802380A1 (en) * 2010-06-28 2012-01-05 Janssen Pharmaceutica Nv 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
CN103403007B (zh) 2010-12-22 2015-12-09 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5,6-二氢-咪唑并[1,2-a]吡嗪-8-基胺衍生物
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
BR112013017988A2 (pt) * 2011-01-13 2019-09-24 Novartis Ag inibidores de bace-2 para o tratamento de distúrbios metabólicos
AU2012206561B2 (en) 2011-01-13 2015-12-17 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
ES2558779T3 (es) 2011-03-01 2016-02-08 Janssen Pharmaceutica, N.V. Derivados de 6,7-dihidro-pirazolo[1,5-a]piracin-4-ilamina útiles como inhibidores de ß-secretasa (BACE)
US9845326B2 (en) 2011-03-09 2017-12-19 Janssen Pharmaceutica Nv Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
CA2832473A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions, and their use
EP2703399A4 (en) 2011-04-26 2014-10-15 Shionogi & Co OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
WO2014099794A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
CN105283457B (zh) 2013-06-12 2018-09-18 詹森药业有限公司 作为β-分泌酶(BACE)抑制剂的4-氨基-6-苯基-5,6-二氢咪唑并[1,5-A]吡嗪衍生物
AU2014280125B2 (en) 2013-06-12 2018-03-15 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE)
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
AU2015367594C1 (en) 2014-12-18 2019-10-31 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (es) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1702919B1 (en) 2003-12-29 2012-05-30 Msd K.K. Novel 2-heteroaryl-substituted benzimidazole derivative
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
CN101346357B (zh) * 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
KR20160067985A (ko) * 2005-11-08 2016-06-14 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US20100048597A1 (en) * 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
PE20091438A1 (es) 2008-01-18 2009-09-26 Eisai Randd Man Co Ltd Derivados fusionados de aminodihidrotiazina
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
SG185652A1 (en) * 2010-06-09 2012-12-28 Janssen Pharmaceutica Nv 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
CA2802380A1 (en) * 2010-06-28 2012-01-05 Janssen Pharmaceutica Nv 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia

Also Published As

Publication number Publication date
CU20120099A7 (es) 2012-07-31
SG181431A1 (en) 2012-07-30
PT2519515E (pt) 2014-02-17
JP2013516395A (ja) 2013-05-13
PE20121640A1 (es) 2012-12-17
ZA201203614B (en) 2013-01-30
NZ600136A (en) 2013-09-27
ECSP12012065A (es) 2012-08-31
WO2011080176A1 (en) 2011-07-07
CN102712621B (zh) 2015-03-11
GT201200219A (es) 2013-10-10
BR112012015916A2 (pt) 2017-04-25
AU2010338365B2 (en) 2014-01-30
CR20120332A (es) 2012-07-12
AU2010338365A1 (en) 2012-06-07
MX2012007754A (es) 2012-08-01
EA201200952A1 (ru) 2013-02-28
TN2012000249A1 (en) 2013-12-12
PL2519515T3 (pl) 2014-04-30
HK1172023A1 (en) 2013-04-12
US20150322038A1 (en) 2015-11-12
ES2445536T3 (es) 2014-03-03
CL2012001762A1 (es) 2012-12-21
EP2519515B1 (en) 2013-11-06
JP5600754B2 (ja) 2014-10-01
KR101419157B1 (ko) 2014-07-11
EP2519515A1 (en) 2012-11-07
US20120277244A1 (en) 2012-11-01
IL220268A0 (en) 2012-07-31
CN102712621A (zh) 2012-10-03
CA2785341A1 (en) 2011-07-07
KR20120102795A (ko) 2012-09-18

Similar Documents

Publication Publication Date Title
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
CO6781507A2 (es) Novedosos derivados heterociclicos
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
UY33458A (es) Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
GT201500159A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY32404A (es) 4-aril-butan-1,3-diamidas
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UY32748A (es) 2-carboxamida-cicloamino-ureas
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
UY33180A (es) Derivados de ácido carboxílico heterocíclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida.